Tools for target identification and validation

被引:62
作者
Wang, SL [1 ]
Sim, TB [1 ]
Chang, YT [1 ]
机构
[1] NYU, Dept Chem, New York, NY 10003 USA
关键词
D O I
10.1016/j.cbpa.2004.06.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Reliable technologies for addressing target identification and validation are the foundation of successful drug development. Microarrays have been well utilized in genomics/proteomics approaches for gene/protein expression profiling and tissue/ cell-scale target validation. Besides being used as an essential step in analyzing high-throughput experiments such as those involving microarrays, bioinformatics can also contribute to the processes of target identification and validation by providing functional information about target candidates and positioning information to biological networks. Antisense technologies (including RNA interference technology, which is recently very 'hot') enable sequence-based gene knockdown at the RNA level. Zinc finger proteins are a DNA transcription-targeting version of knockdown. Chemical genomics and proteomics are emerging tools for generating phenotype changes, thus leading to target and hit identifications. NMR-based screening, as well as activity-based protein profiling, are trying to meet the requirement of high-throughput target identification.
引用
收藏
页码:371 / 377
页数:7
相关论文
共 44 条
[11]   Discovery of novel targets of quinoline drugs in the human purine binding proteome [J].
Graves, PR ;
Kwiek, JJ ;
Fadden, P ;
Ray, R ;
Hardeman, K ;
Coley, AM ;
Foley, M ;
Haystead, TAJ .
MOLECULAR PHARMACOLOGY, 2002, 62 (06) :1364-1372
[12]   RNA interference [J].
Hannon, GJ .
NATURE, 2002, 418 (6894) :244-251
[13]   NK1 (substance P) receptor antagonists -: why are they not analgesic in humans? [J].
Hill, R .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (07) :244-246
[14]   Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling [J].
Hirst, WD ;
Abrahamsen, B ;
Blaney, FE ;
Calver, AR ;
Aloj, L ;
Price, GW ;
Medhurst, AD .
MOLECULAR PHARMACOLOGY, 2003, 64 (06) :1295-1308
[15]   Collecting and harvesting biological data: the GPCRDB and NucleaRDB information systems [J].
Horn, F ;
Vriend, G ;
Cohen, FE .
NUCLEIC ACIDS RESEARCH, 2001, 29 (01) :346-349
[16]   Developments in microarray technologies [J].
Howbrook, DN ;
van der Valk, AM ;
O'Shaughnessy, MC ;
Sarker, DK ;
Baker, SC ;
Lloyd, AW .
DRUG DISCOVERY TODAY, 2003, 8 (14) :642-651
[17]  
JACQUES D, 2001, EXPERT OPIN THER PAT, V11, P405
[18]   Drug discovery with engineered zinc-finger proteins [J].
Jamieson, AC ;
Miller, JC ;
Pabo, CO .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :361-368
[19]   In silico model-driven assessment of the effects of single nucleotide Polymorphisms (SNPs) on human red blood cell metabolism [J].
Jamshidi, N ;
Wiback, SJ ;
Palsson, BO .
GENOME RESEARCH, 2002, 12 (11) :1687-1692
[20]   Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness [J].
Jessani, N ;
Liu, YS ;
Humphrey, M ;
Cravatt, BF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (16) :10335-10340